191 results about "Recurrent anxiety" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention provides an application of a fermentation lactobacillus mucus strain A21196 in preparation of a product for resisting anxiety and improving memory and concentration, and belongs to the technical field of biological medicines. Animal experiments show that the fermented lactobacillus mucus strain A21196 has the effects of resisting anxiety, resisting depression, improving cognitive impairment function and improving memory concentration, and provides a new means for preventing and / or treating nerve diseases related to anxiety disorder, depression and cognitive impairment.

A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and / or measures of depression (HDRS or BDI scores) and / or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present disclosure provides a method of treating a symptom or preventing a symptom of generalized anxiety disorder comprising administering an orally disintegrating tablet comprising LSD, or a salt thereof, to a subject in need thereof.

The invention discloses a traditional Chinese medicine composition for treating depression as well as a preparation method and application of the traditional Chinese medicine composition. The preparation method comprises the following steps: weighing vinegar-processed rhizoma cyperi, ligusticum wallichii, fried rhizoma atractylodis, fried medicated leaven and fried fructus gardeniae which are equal in mass; crushing and sieving the vinegar rhizoma cyperi, the ligusticum wallichii, the fried rhizoma atractylodis and the fried medicated leaven to obtain traditional Chinese medicine powder; placing the traditional Chinese medicine powder in a 60-80% ethanol solution for decoction extraction, filtering, collecting filtrate, repeatedly extracting for 2-4 times, merging the filtrate, concentrating and drying to obtain thick paste; the fried cape jasmine is smashed and sieved, cape jasmine powder is obtained, then the cape jasmine powder and the thick paste are mixed, and the traditional Chinese medicine composition for treating depression is obtained. The preparation method disclosed by the invention can be used for efficiently and fully extracting active ingredients, such as ligustilide, atractydin I and alpha-cyperone, in the traditional Chinese medicine raw materials to obtain a new extract which is excellent in medicine effect, clear in ingredients and free from obvious toxic and side effects, and is expected to be developed as a novel medicine for improving and / or treating depression and anxiety disorder.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

Methods, systems and devices for reducing anxiety, including increasing relaxation and / or calm. In some variations these methods may include reducing anxiety, increase relaxation and / or calm by non-invasive temperature regulation of the frontal cortex prior to and / or during sleep. The subject may have an anxiety disorder, or may not have a diagnosed anxiety disorder.

The invention relates to the field of breeding technical equipment, and particularly provides protein expression profile screening and application of anxiety disorder of Alzheimer's disease. Specifically, for Alzheimer's disease anxiety disorder caused by amyloid beta protein accumulation, proteomics analysis finds that inhibition of aBLA-vCA1 pathway functions can effectively relieve social avoidance behaviors caused by amyloid beta protein accumulation; and the differential functional proteins of the anxiety disorder of the Alzheimer's disease, such as RPS6, UBQLN1, Eras2, Rpl30, SERBP1, CLU, APOE, C4B, C1QB, C1QA, C1QC, MAPK1, MAPK3, RHOG, PTK2B, ASPA, GAD1, GAD2, H3f3a, H4C8 and TSPYL4, are screened out. The different functional proteins can be used as biomarkers for detecting Alzheimer's disease anxiety disorder caused by accumulation of pulverulent beta protein, and can be used as potential therapeutic targets.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention provides an application of a pediococcus pentosaceus strain A20001 in preparation of a product for improving memory concentration and anxiety and depression behaviors, and belongs to the technical field of biological medicines. Animal experiments show that the pediococcus pentosaceus strain A20001 has the functions of resisting anxiety behavior, resisting depression, improving cognitive function and improving memory concentration. Therefore, the invention provides the application of the pediococcus pentosaceus strain A20001 in the preparation of the medicine for preventing and / or treating the anxiety disorder, the depression or the cognitive impairment and improving the memory, and further provides the application of the pediococcus pentosaceus strain A20001 in the preparation of the medicine for preventing and / or treating the anxiety disorder, the depression or the cognitive impairment.

This invention pertains to a cognitive-coping therapy (CCT) method, system, and application that is a computer-implemented method for implementing AI-based CCT for a patient using natural language processing (NLP) and / or human-machine dialogue with / without an avatar. Based on the cognitive psychology and stress-coping theory, the CCT alleviates the excessive fear of negative event(s) and can be used to address mental disorders / conditions like obsessive-compulsive disorder (OCD), anxiety disorders (e.g., panic disorder, social phobia), and more. The AI system uses the NLP to comprehend the patient's symptoms and provide relevant interventions. Additionally, the system can monitor the patient's progress over time and adapt the interventions accordingly.

The present invention relates to the use of STING agonists in depression or anxiety disorders. Specifically, the compound disclosed by the invention is described in the specification, and the compound disclosed by the invention has an excellent prevention and / or treatment effect on depression and / or anxiety disorder.

The invention discloses a traditional Chinese medicine composition for treating breast cancer complicated with anxiety disorder as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is mainly prepared from the following raw material medicines: astragalus membranaceus, herba epimedii, ligusticum wallichii, semen boitae, acanthopanax, rhizoma drynariae, selfheal, arisaema cum bile, turtle shell, nigrum fruit, salvia chinensis and artemisia apiacea. The invention further discloses a preparation method of the traditional Chinese medicine composition, a pharmaceutical preparation and application. Pharmacodynamic experiments prove that the traditional Chinese medicine composition can remarkably inhibit tumor growth of anxiety tumor-bearing mice and improve anxiety behavioral indexes, achieves dual treatment targets of tumor resistance and emotion regulation, and is particularly suitable for middle and advanced breast cancer combined anxiety patient groups needing long-term treatment.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating hashimoto thyroiditis related depression anxiety disorder and application. The traditional Chinese medicine composition comprises astragalus membranaceus, radix pseudostellariae, bighead atractylodes rhizome, pericarpium citri reticulatae, selfheal, thunberg fritillary bulb, oyster, rhizoma cyperi, angelica sinensis, radix bupleuri and liquorice. The traditional Chinese medicine composition can effectively improve the thyroid lymphocyte infiltration degree and the overall inflammatory response level of AIT mice, effectively reduce the number of depression behaviors of the mice and relieve the depression anxiety state. According to the traditional Chinese medicine composition disclosed by the invention, the effects of all the medicines generate a synergistic effect and can be prepared into a traditional Chinese medicine preparation, so that depression and anxiety disorders related to hashimoto thyroiditis can be effectively treated.

The invention discloses an intestinal flora marker and application thereof in diagnosis and treatment of anxiety disorder. According to the present invention, the intestinal flora marker comprises a specific strain Lacnospiraceae bacterium.1 of the genus of Horsespirillum, Odorobacter splanchnicus, Coprococcus dexterous, and Clostridium aldenense, and the intestinal flora marker comprises a specific strain Lacnospiraceae bacterium.1 of the genus of Horsespirillum, Odorobacter splanchnicus, Coprococcus dexterous, and Clostridium aldenense, the ROC curve analysis of the intestinal flora marker as a detection variable of anxiety disorder has high specificity and sensitivity, so that the intestinal flora marker can be used as a detection marker to be applied to diagnosis of anxiety disorder patients. The intestinal flora marker disclosed by the invention is used as a detection marker of anxiety disorder, is completely noninvasive and is high in accuracy.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention relates to the technical field of patient psychological nursing, in particular to a neurology patient psychological nursing analysis system and method based on an intelligent chip, and the method comprises the steps: analyzing the difference degree of the physiological characteristics of an anxiety patient before and after an operation based on preoperative physiological characteristic data and postoperative physiological characteristic data; based on the symptom reaction data and the operation data of the anxiety patient, analyzing the operation complexity of the anxiety patient; according to the physiological feature difference degree analysis result before and after the operation and the operation complexity degree analysis result, the psychological stress risk of the anxiety disorder patient is evaluated; according to the psychological stress risk assessment result, patient psychological nursing early warning is given to medical staff, by accurately quantifying the psychological stress risk, the high-risk patient can be recognized in the early stage, postoperative acute anxiety, delirium and other complications are avoided, and the operation safety and rehabilitation quality are remarkably improved.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention provides an application of a lactobacillus plantarum strain A21337 in preparation of a product for resisting anxiety and improving memory and concentration, and belongs to the technical field of biological medicines. Animal experiments show that the plant lactobacillus strain A21337 has the effects of resisting anxiety, resisting depression, improving cognitive impairment function and improving memory concentration, and a new means is provided for preventing and / or treating nerve diseases related to anxiety disorder, depression and cognitive impairment.

In alternative embodiments, provided are products of manufacture, including devices and integrated systems, and methods, for reducing error-related negativity (ERN) and anxiety, and for treating or ameliorating Anxiety Disorders such as Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD) and obsessive-compulsive disorder (OCD).

The invention belongs to the technical field of biological medicine, and particularly provides application of EAAT2 as a drug target to screening of drugs for improving anxiety disorder. The drug target EAAT2 is mainly expressed on astrocytes, the research finds that the expression level of the EAAT2 is closely related to the anxiety state, and the anxiety disorder can be improved by regulating and controlling the target through a specific compound and a specific adenovirus vector. A brand-new drug target and a new treatment means and thought are provided for treatment of anxiety disorder and drug research and development.